文献速递神经肿瘤

口服5-氨基乙酰丙酸在成人新诊断或复发高级别胶质瘤切除术中的1期剂量递增研究

A Phase 1 Dose-Escalation Study of Oral 5-Aminolevulinic Acid in Adult Patients Undergoing Resection of a Newly Diagnosed or Recurrent High-Grade Glioma.
PubMed 文献 · Neurosurgery · 2017-01-01

这项在美国单医疗中心开展的1期剂量递增研究纳入19例拟行高级别胶质瘤切除术的成人患者,术前口服5-氨基乙酰丙酸(5-ALA),剂量从10至50 mg/kg、每10 mg/kg递增,至少3例/剂量级。严重不良事件与5-ALA摄入无关;最高剂量50 mg/kg组6例中2例出现一过性皮肤发红脱屑(1级,未达剂量限制);>40 mg/kg组更易出现强肿瘤荧光;无假阳性荧光。作者认为5-ALA用于脑肿瘤荧光安全有效至50 mg/kg,未达剂量限制毒性。

要点

  • 19例患者中严重不良事件与口服5-ALA无关。
  • 50 mg/kg组6例中2例出现1级一过性皮肤发红脱屑,未达剂量限制。
  • >40 mg/kg剂量组更易出现强肿瘤荧光,无假阳性荧光。

核心结论

  • 作者认为5-ALA用于脑肿瘤荧光安全有效至50 mg/kg,本研究未达到剂量限制毒性。

研究设计与样本

  • 美国单医疗中心开展的1期快速剂量递增研究,纳入19例拟行高级别胶质瘤切除术的成人患者。
  • 5-ALA口服剂量从10至50 mg/kg、每10 mg/kg递增,每个剂量级至少选3例患者。
  • 记录不良事件、肿瘤荧光强度以及白光和深蓝光下肿瘤区和瘤床活检结果。

主要发现

  • 严重不良事件与5-ALA摄入无关。
  • 最高研究剂量50 mg/kg组6例中2例出现一过性皮肤发红和脱屑,为1级不良事件,未严重到构成剂量限制。
  • 较高剂量组(>40 mg/kg)更可能出现强肿瘤荧光。
  • 无假阳性荧光病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The utility of oral 5-aminolevulinic acid (5-ALA)/protoporphyrin fluorescence for the resection of high-grade gliomas is well documented. This drug has received regulatory approval in Europe but awaits approval in the United States. OBJECTIVE: To identify the appropriate dose and toxicity or harms of 5-ALA used for enhanced intraoperative visualization of malignant brain tumors, reported from a single medical center in the United States. METHODS: Prior to craniotomy for resection of a presumed high-grade glioma, individuals were given oral 5-ALA as part of a rapid dose-escalation scheme. At least 3 patients were selected for each dose level from 10 to 50 mg/kg in 10 mg/kg increments. Adverse events, intensity of tumor fluorescence, and results of biopsies in areas of tumor and the tumor bed under white light and deep blue light were recorded. RESULTS: A total of 19 patients were studied in this phase 1 study. Serious adverse events were unrelated to the ingestion of 5-ALA. At the highest dose level studied (50 mg/kg), 2 out of 6 patients were observed to have transient dermatologic redness and peeling. These were grade 1 adverse events, which were not serious enough to be dose limiting. Patients at higher dose levels (>40 mg/kg) were more likely to have strong tumor fluorescence. There were no instances of false positive fluorescence. CONCLUSION: The use of 5-ALA for brain tumor fluorescence is safe and effective to a dose of 50 mg/kg. Dose-limiting toxicity was not reached in this study.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Cozzens JW, Lokaitis BC, Moore BE, et al. A Phase 1 Dose-Escalation Study of Oral 5-Aminolevulinic Acid in Adult Patients Undergoing Resection of a Newly Diagnosed or Recurrent High-Grade Glioma. Neurosurgery. 2017. PMID: 28498936. doi:10.1093/neuros/nyw182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。